Amyloid-beta and Tau Protein Beyond Alzheimer's Disease

Overview

Journal Neural Regen Res

Date 2023 Oct 31

PMID 37905874

Authors

Morteza Abyadeh

Vivek Gupta

Joao A Paulo

Arezoo Gohari Mahmoudabad

Sina Shadfar

Shahab Mirshahvaladi

Veer Gupta

Christine T O Nguyen

David I Finkelstein

Yuyi You

Paul A Haynes

Ghasem H Salekdeh

Stuart L Graham

Mehdi Mirzaei

Affiliations

Soon will be listed here.

Abstract

The aggregation of amyloid-beta peptide and tau protein dysregulation are implicated to play key roles in Alzheimer's disease pathogenesis and are considered the main pathological hallmarks of this devastating disease. Physiologically, these two proteins are produced and expressed within the normal human body. However, under pathological conditions, abnormal expression, post-translational modifications, conformational changes, and truncation can make these proteins prone to aggregation, triggering specific disease-related cascades. Recent studies have indicated associations between aberrant behavior of amyloid-beta and tau proteins and various neurological diseases, such as Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis, as well as retinal neurodegenerative diseases like Glaucoma and age-related macular degeneration. Additionally, these proteins have been linked to cardiovascular disease, cancer, traumatic brain injury, and diabetes, which are all leading causes of morbidity and mortality. In this comprehensive review, we provide an overview of the connections between amyloid-beta and tau proteins and a spectrum of disorders.

Citing Articles

Therapeutic Role of Heterocyclic Compounds in Neurodegenerative Diseases: Insights from Alzheimer's and Parkinson's Diseases.

Puranik N, Song M Neurol Int. 2025; 17(2).

PMID: 39997657 PMC: 11858632. DOI: 10.3390/neurolint17020026.

Amyloid-β and heart failure in Alzheimer's disease: the new vistas.

Al-Kuraishy H, Sulaiman G, Mohammed H, Mohammed S, Al-Gareeb A, Albuhadily A Front Med (Lausanne). 2025; 12:1494101.

PMID: 39967593 PMC: 11832649. DOI: 10.3389/fmed.2025.1494101.

Behavioral and histological study on the neuroprotective effect of thymoquinone on the cerebellum in AlCl3-induced neurotoxicity in rats through modulation of oxidative stress, apoptosis, and autophagy.

Shrief A, Elshenawy D, Elsukary A, Elekhtiar S, Yahia O J Mol Histol. 2025; 56(2):81.

PMID: 39912993 DOI: 10.1007/s10735-025-10361-2.

The neuroprotective role of volatile oils: insights into chemical profiles, characteristics, neurochemical mechanisms, and preclinical studies in Alzheimer's disease.

Suryawanshi M, Gujarathi P, Prajapati B, Vinchurkar K, Gujarathi P Inflammopharmacology. 2025; 33(2):627-667.

PMID: 39841377 DOI: 10.1007/s10787-024-01626-5.

The Search for a Universal Treatment for Defined and Mixed Pathology Neurodegenerative Diseases.

ODay D Int J Mol Sci. 2025; 25(24.

PMID: 39769187 PMC: 11678063. DOI: 10.3390/ijms252413424.

References

Meisl G, Yang X, Hellstrand E, Frohm B, Kirkegaard J, Cohen S . Differences in nucleation behavior underlie the contrasting aggregation kinetics of the Aβ40 and Aβ42 peptides. Proc Natl Acad Sci U S A. 2014; 111(26):9384-9. PMC: 4084462. DOI: 10.1073/pnas.1401564111. View

Jellinger K . Alzheimer-type lesions in Huntington's disease. J Neural Transm (Vienna). 1998; 105(8-9):787-99. DOI: 10.1007/s007020050095. View

Kaarniranta K, Salminen A, Haapasalo A, Soininen H, Hiltunen M . Age-related macular degeneration (AMD): Alzheimer's disease in the eye?. J Alzheimers Dis. 2011; 24(4):615-31. DOI: 10.3233/JAD-2011-101908. View

Chan J, Chan N, Sadun A . Glaucoma as Neurodegeneration in the Brain. Eye Brain. 2021; 13:21-28. PMC: 7822087. DOI: 10.2147/EB.S293765. View

Craft S, Baker L, Montine T, Minoshima S, Watson G, Claxton A . Intranasal insulin therapy for Alzheimer disease and amnestic mild cognitive impairment: a pilot clinical trial. Arch Neurol. 2011; 69(1):29-38. PMC: 3260944. DOI: 10.1001/archneurol.2011.233. View

Kadak M, Cetin I, Tarakcioglu M, Ozer O, Kacar S, Cimen B . Low Serum Level α-Synuclein and Tau Protein in Autism Spectrum Disorder Compared to Controls. Neuropediatrics. 2015; 46(6):410-5. DOI: 10.1055/s-0035-1565273. View

Filippi M, Bar-Or A, Piehl F, Preziosa P, Solari A, Vukusic S . Multiple sclerosis. Nat Rev Dis Primers. 2018; 4(1):43. DOI: 10.1038/s41572-018-0041-4. View

Santos C, Snyder P, Wu W, Zhang M, Echeverria A, Alber J . Pathophysiologic relationship between Alzheimer's disease, cerebrovascular disease, and cardiovascular risk: A review and synthesis. Alzheimers Dement (Amst). 2017; 7:69-87. PMC: 5328683. DOI: 10.1016/j.dadm.2017.01.005. View

Rouzier R, Rajan R, Wagner P, Hess K, Gold D, Stec J . Microtubule-associated protein tau: a marker of paclitaxel sensitivity in breast cancer. Proc Natl Acad Sci U S A. 2005; 102(23):8315-20. PMC: 1149405. DOI: 10.1073/pnas.0408974102. View

10.

Masliah E, Rockenstein E, Veinbergs I, Sagara Y, Mallory M, Hashimoto M . beta-amyloid peptides enhance alpha-synuclein accumulation and neuronal deficits in a transgenic mouse model linking Alzheimer's disease and Parkinson's disease. Proc Natl Acad Sci U S A. 2001; 98(21):12245-50. PMC: 59799. DOI: 10.1073/pnas.211412398. View

11.

Hu W, Chen-Plotkin A, Arnold S, Grossman M, Clark C, Shaw L . Biomarker discovery for Alzheimer's disease, frontotemporal lobar degeneration, and Parkinson's disease. Acta Neuropathol. 2010; 120(3):385-99. PMC: 2982700. DOI: 10.1007/s00401-010-0723-9. View

12.

Iadecola C, Zhang F, Niwa K, Eckman C, Turner S, FISCHER E . SOD1 rescues cerebral endothelial dysfunction in mice overexpressing amyloid precursor protein. Nat Neurosci. 1999; 2(2):157-61. DOI: 10.1038/5715. View

13.

Cataldo A, Peterhoff C, Troncoso J, Gomez-Isla T, Hyman B, Nixon R . Endocytic pathway abnormalities precede amyloid beta deposition in sporadic Alzheimer's disease and Down syndrome: differential effects of APOE genotype and presenilin mutations. Am J Pathol. 2000; 157(1):277-86. PMC: 1850219. DOI: 10.1016/s0002-9440(10)64538-5. View

14.

Sadigh-Eteghad S, Sabermarouf B, Majdi A, Talebi M, Farhoudi M, Mahmoudi J . Amyloid-beta: a crucial factor in Alzheimer's disease. Med Princ Pract. 2014; 24(1):1-10. PMC: 5588216. DOI: 10.1159/000369101. View

15.

Abyadeh M, Tofigh N, Hosseinian S, Hasan M, Amirkhani A, Fitzhenry M . Key Genes and Biochemical Networks in Various Brain Regions Affected in Alzheimer's Disease. Cells. 2022; 11(6). PMC: 8946735. DOI: 10.3390/cells11060987. View

16.

dErrico P, Meyer-Luehmann M . Mechanisms of Pathogenic Tau and Aβ Protein Spreading in Alzheimer's Disease. Front Aging Neurosci. 2020; 12:265. PMC: 7481386. DOI: 10.3389/fnagi.2020.00265. View

17.

Zayas-Santiago A, Diaz-Garcia A, Nunez-Rodriguez R, Inyushin M . Accumulation of amyloid beta in human glioblastomas. Clin Exp Immunol. 2020; 202(3):325-334. PMC: 7670151. DOI: 10.1111/cei.13493. View

18.

McCormack A, Chegeni N, Chegini F, Colella A, Power J, Keating D . Purification of α-synuclein containing inclusions from human post mortem brain tissue. J Neurosci Methods. 2016; 266:141-50. DOI: 10.1016/j.jneumeth.2016.03.016. View

19.

Soragni A, Zambelli B, Mukrasch M, Biernat J, Jeganathan S, Griesinger C . Structural characterization of binding of Cu(II) to tau protein. Biochemistry. 2008; 47(41):10841-51. DOI: 10.1021/bi8008856. View

20.

Hamilton R . Lewy bodies in Alzheimer's disease: a neuropathological review of 145 cases using alpha-synuclein immunohistochemistry. Brain Pathol. 2000; 10(3):378-84. PMC: 8098522. DOI: 10.1111/j.1750-3639.2000.tb00269.x. View